ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of$750M per target ProFound to leverage its ProFoundry™ Platform to mine the expanded proteome to identify previously unknown proteins as novel drug targets for cardiovascular disease CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProFound™ Therapeutics, a company pioneering the expanded human proteome to develop first-in-class medicines for multiple diseases, today announced a four- ...